Medicines/Item |
Section |
Status |
Link Name / Link URL |
Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
Adalimumab |
13.05.03 |
Formulary
|
Adalimumab for the treatment of adults with psoriasis |
Adalimumab |
13.05.03 |
Formulary
|
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
Adalimumab |
01.05.03 |
Formulary
|
NICE TA460 : Adalimumab and dexamethasone for treating non-infectious uveitis |
Adefovir Dipivoxil |
05.03.03.01 |
Non Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
Adefovir Dipivoxil |
05.03.03.01 |
Non Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
Aflibercept |
08.01.05 |
Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
Alemtuzumab |
08.02.03 |
Non Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TA156: Anti-D in pregnant women |
Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for AF |
Apremilast |
13.05.03 |
Non Formulary
|
NICE TA433 : Apremilast for treating active psoriatic arthritis |
Apremilast |
13.05.03 |
Non Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
Apremilast |
13.05.03 |
Non Formulary
|
NICE TA372: Apremilast for psoriatic arthritis |
Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA448 : Etelcalcetide for treating secondary hyperparathyroidism |
Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
Aquacel Extra |
A5.02.04 |
Non Formulary
|
NICE TA456: Baricitinib for moderate to severe rheumatoid arthritis |
Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
Atezolizumab |
08.01.05 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
Atezolizumab |
08.01.05 |
Formulary
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
Azacitidine |
08.01.03 |
Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
Baricitinib |
10.01.03 |
Formulary
|
Baricitinib for moderate to severe rheumatoid arthritis |
Basiliximab |
08.02.02 |
Non Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
Basiliximab |
08.02.02 |
Non Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
Belimumab |
10.01 |
Non Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
Bisphosphonates |
09.05.01.02 |
Non Formulary
|
NICE TA464 : Bisphosphonates for treating osteoporos |
Bivalirudin |
02.08.01 |
Non Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
Blinatumomab |
08.02 |
Non Formulary
|
NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
Boceprevir |
05.03.03.02 |
Non Formulary
|
NICE TA253: hepatitis |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: 1st line treatment of multiple myeloma |
Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
Bosutinib |
08.01.05 |
Non Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524 : Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
Brodalumab |
13.05.03 |
Formulary
|
Brodalumab for treating moderate to severe plaque psoriasis |
Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma |
Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Cangrelor |
02.09 |
Non Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer |
Carfilzomib |
08.01.05 |
Non Formulary
|
NICE TA457 : Carfilzomib for previously treated multiple myeloma |
Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD |
Cetuximab |
08.01.05 |
Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Ciclosporin 0.1% |
11.08.01 |
Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
Cladribine |
08.01.03 |
Non Formulary
|
NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis |
Clearfilm |
A5.02.02 |
Non Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
Colecalciferol 800 units |
09.06.04 |
Non Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
Colistimethate inhaler |
05.01.07 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
Collagenase |
10.03.01 |
Non Formulary
|
NICE TA459 : Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
Conjugated oestrogens + Bazedoxifene |
06.04.01.01 |
Non Formulary
|
NICE TA443 : Obeticholic acid for treating primary biliary cholangitis |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
Dabrafenib |
08.01.05 |
Non Formulary
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
Dabrafenib |
08.01.05 |
Non Formulary
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Daclatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
Daclizumab |
08.02.02 |
Non Formulary
|
NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes |
Daratumumab |
08.01.05 |
Formulary
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
Daratumumab |
08.01.05 |
Formulary
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
Dasabuvir |
05.03.03.02 |
Non Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Dasatinib |
08.01.05 |
Non Formulary
|
NICE TA241: CML where treatment with imatinib has failed |
Dasatinib |
08.01.05 |
Non Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Dasatinib |
08.01.05 |
Non Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
Dexamethasone intravitreal implant |
11.04.01 |
Non Formulary
|
NICE TA349: Diabetic Macular Oedema |
Dimethyl fumarate |
08.02.04 |
Non Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
Dimethyl fumarate |
08.02.04 |
Non Formulary
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
Docetaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
Dornase Alfa |
03.07 |
Formulary
|
NICE NG78: Cystic fibrosis: diagnosis and management |
Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation |
Dupilumab |
13.05.03 |
Formulary
|
Dupilumab for treating moderate to severe atopic dermatitis |
Durvalumab |
08.01.05 |
Formulary
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation |
Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
Emtricitabine + rilpivirine + tenofovir alafenamide |
05.03.01 |
Non Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
Entecavir |
05.03.03.01 |
Non Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
Entecavir |
05.03.03.01 |
Non Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer |
Eplerenone |
02.02.03 |
Formulary
|
NICE NG106: Chronic heart failure in adults: diagnosis and management |
Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
Etanercept |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Etanercept |
13.05.03 |
Non Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
Everolimus |
08.01.05 |
Non Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Everolimus |
08.01.05 |
Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Everolimus |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Exenatide |
06.01.02.03 |
Formulary
|
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes |
Exenatide prolonged release |
06.01.02.03 |
Non Formulary
|
NICE TA248: MR exenatide |
Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout |
Febuxostat |
10.01.04 |
Non Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
Fingolimod |
08.02.04 |
Non Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE YA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
Glatiramer Acetate |
08.02.04 |
Non Formulary
|
NICE CG32: Glatiramer for the treatment of MS |
Glecaprevir / Pibrentasvir |
05.03.03.02 |
Non Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
Golimumab |
10.01.03 |
Formulary
|
NICE TA220: Golimumab for the treatment of psoriatic arthritis |
Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Golimumab |
10.01.03 |
Non Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Guselkumab |
13.05.03 |
Formulary
|
Guselkumab for treating moderate to severe plaque psoriasis |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
Idelalisib |
08.01.05 |
Non Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
Infliximab |
01.05.03 |
Non Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
Infliximab |
01.05.03 |
Non Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Infliximab |
01.05.03 |
Non Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab |
13.05.03 |
Non Formulary
|
NICE TA134: Infliximab for psoriasis |
Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
Injection Device |
06.01.01.03 |
Non Formulary
|
NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis |
Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
Ipilimumab |
08.01.05 |
Non Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
Ipilimumab |
08.01.05 |
Non Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Ipilimumab |
08.01.05 |
Non Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: Ivabradine for treating chronic heart failure |
Ivabradine |
02.06.03 |
Non Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
Ixazomib |
08.01.05 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
Labetalol |
02.04 |
Formulary
|
NICE NG133: Hypertension in pregnancy: diagnosis and management |
Lamivudine |
05.03.01 |
Non Formulary
|
NICE CG165: Chronic Hepatitis B |
Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Ledipasvir and Sofosbuvir |
05.03.03.02 |
Non Formulary
|
NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
Ledipasvir and Sofosbuvir |
05.03.03.02 |
Non Formulary
|
NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
Lenvatinib |
08.01.05 |
Non Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
Lesinurad |
10.01.04 |
Non Formulary
|
NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout |
Lubiprostone |
01.06.07 |
Non Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
Mannitol inhalation |
03.07 |
Non Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
Mepolizumab |
03.04.02 |
Non Formulary
|
NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma |
Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
Mifamurtide |
08.02.04 |
Non Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
Milrinone |
02.01.02 |
Non Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
Nalmefene |
04.10.01 |
Restricted Use
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
Naltrexone/ bupropion |
04.05.01 |
Non Formulary
|
Nice TA494: Naltrexone–bupropion for managing overweight and obesity |
Natalizumab |
08.02.04 |
Non Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
Nintedanib |
03.11 |
Non Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
Nintedanib |
03.11 |
Non Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
Nivolumab |
08.02.04 |
Formulary
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
Obinutuzumab |
08.02.03 |
Non Formulary
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
Obinutuzumab |
08.02.03 |
Non Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
Olaparib |
08.02.04 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
Olaparib |
08.02.04 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
Omalizumab |
03.04.02 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Non Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
Osimertinib |
08.02.04 |
Formulary
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
Pablociclib |
08.01.05 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Pablociclib |
08.01.05 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Paclitaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Non Formulary
|
NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine |
Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Panitumumab |
08.01.05 |
Non Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Panobinostat |
08.01.05 |
Non Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
Pazopanib |
08.01.05 |
Non Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
Pegaspargase |
08.01 |
Non Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531 : Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
Perampanel |
04.08.01 |
Non Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Pirfenidone |
03.11 |
Formulary
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
Pixantrone |
08.01.02 |
Non Formulary
|
NICE TA306: Pixantrone monotherapy |
Pomalidomide |
08.02.04 |
Non Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
Pomalidomide |
08.02.04 |
Non Formulary
|
NICE TA388: Pomalidomide for myeloma |
Ponatinib |
08.01.05 |
Non Formulary
|
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
Prasugrel |
02.09 |
Formulary
|
NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes |
Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Prucalopride for the treatment of chronic constipation in women |
Radium-223 dichloride |
08.03.04.02 |
Non Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
Radium-223 dichloride |
08.03.04.02 |
Non Formulary
|
NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
Regorafenib |
08.01.05 |
Non Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
Reslizumab |
03.04.02 |
Non Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
Retigabine |
04.08.01 |
Non Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
Rifaximin |
05.01.07 |
Formulary
|
Rifaximin for preventing episodes of overt hepatic encephalopathy TA337 |
Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
Risankizumab |
13.05.03 |
Formulary
|
Risankizumab for treating moderate to severe plaque psoriasis |
Rituximab (rheumatology) |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
Roflumilast |
03.03.03 |
Formulary
|
NICE TA461 : Roflumilast for treating chronic obstructive pulmonary disease |
Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
Sarilumab |
10.01.03 |
Non Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
Secukinumab |
10.01.03 |
Formulary
|
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Plaque Psoriasis |
Secukinumab |
13.05.03 |
Formulary
|
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
Sofosbuvir |
05.03.03.02 |
Non Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
Sofosbuvir and Velpatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Somatropin for growth failure in children |
Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) |
Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
Sunitinib |
08.01.05 |
Non Formulary
|
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
Talimogene laherparepvec |
08.01.05 |
Non Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
Temozolomide |
08.01.05 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
Temozolomide |
08.01.05 |
Non Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for relapsing remitting MS |
Teriflunomide |
08.02.04 |
Formulary
|
NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
Tobramycin inhaler |
05.01.04 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247:Tocilizumab in RA |
Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
Tofacitinib citrate |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
Trametinib |
08.01.05 |
Non Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
Trastuzumab emtansine |
08.01.05 |
Non Formulary
|
NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
Ustekinumab |
01.05.03 |
Formulary
|
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
Ustekinumab |
01.05.03 |
Formulary
|
Ustekinumab for treating moderately to severely active ulcerative colitis |
Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
Vemurafenib |
08.01.05 |
Non Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
Verteporfin |
11.08.02 |
Non Formulary
|
NICE TA68: Photodynamic therapy for age related macular degeneration |
Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
Vismodegib |
08.01.05 |
Non Formulary
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
Vitamin B & C high potency injection |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
Vitamin B & C high potency injection |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
Vortioxetine |
04.03.04 |
Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |